BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Apr 25, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

BG-12: Additional Phase III data

Additional data from the double-blind, international Phase III DEFINE trial in >1,200 patients showed that twice-daily 240 mg oral BG-12 significantly reduced the proportion of patients who relapsed at 2 years, the primary endpoint, by 49% vs. placebo (p<0.0001). On secondary endpoints, BG-12 significantly reduced ARR and disability progression as measured by the EDSS by 53% and 38%, respectively, vs. placebo at 2 years. BG-12 also significantly reduced the number of new...

Read the full 340 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >